Page 72 - Haematologica Vol. 107 - September 2022

ARTICLE - Outcome of r/r B-ALL with extramedullary disease S. Kayser et al.
8. Thomas DA, Kantarjian H, Smith TL, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999;86(7):1216-1230.
9. Oriol A, Vives S, Hernández-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica. 2010;95(4):589-596.
10. Tavernier E, Boiron JM, Huguet F, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007;21(9):1907-1914.
11. Gökbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032-2041.
12. Specchia G, Pastore D, Carluccio P, et al. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. Ann Hematol. 2005;84(12):792-795.
13. O’Brien S, Schiller G, Lister J, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome negative acute lymphoblastic leukemia. J Clin Oncol. 2013;31(6):676-683.
14. Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836-847.
15. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(9):740-753.
16. DiJoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B- lymphoid malignancies. Blood. 2004;103(5):1807-1814.
17. Shor B, Gerber HP, Sapra P. Preclinical and clinical development of Inotuzumab-ozogamicin in hematological malignancies. Mol Immunol. 2015;67(2 Pt A):107-116.
18. Lau KM, Saunders IM, Goodman AM. Characterization of relapse patterns in patients with acute lymphoblastic leukemia treated with blinatumomab. J Oncol Pharm Pract. 2021;27(4):821-826.
19. Aldoss I, Song J, Stiller T, et al. Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2017;92(9):858-865.
20. Mitelman F. ISCN: An International System for Human Cytogenetic Nomenclature. S. Karger: Basel, Switzerland;1995.
21. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343-346.
22. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
23. Mantel N, Byar D. Evaluation of response-time data involving transient states: an illustration using heart transplant data. J Am Stat Assoc. 1974;69(345):81-86.
24. Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med. 1984;3(1):35-44.
25. Andersen P, Gill RD. Cox’s regression model for counting processes: a large sample study. Ann Stat. 1982;10(4):1100-1120.
26. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria, 2014.
27. Geethakumari PR, Hoffmann MS, Pemmaraju N, et al. Extramedullary B lymphoblastic leukemia/lymphoma (B-ALL/B- LBL): a diagnostic challenge. Clin Lymphoma Myeloma Leuk.
2014;14(4):e115-e118.
28. Silva WFD, Marquez GL, Salim RC, Rocha V. Primary refractory B-
cell lymphoblastic leukemia with extramedullary disease - a distinctive response to blinatumomab and inotuzumab ozogamicin. Hematol Transfus Cell Ther. 2019;41(4):356-359.
29. Lucas DR, Bentley G, Dan ME, Tabaczka P, Poulik JM, Mott MP. Ewing sarcoma vs lymphoblastic lymphoma. Am J Clin Pathol. 2001;115(1):11-17.
30. DeAngelo DJ, Advani AS, Marks DI, et al. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer J. 2020;10(8):81.
31. Bertamini L, Nanni J, Marconi G, et al. Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia. BMC Cancer. 2018;18(1):1117.
32. Lee SH, Yoon JH, Min GJ, et al. Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study. Int J Hematol. 2022;115(1):135-139.
33. Sanders S, Stewart DA. Targeting non-Hodgkin lymphoma with blinatumomab. Expert Opin Biol Ther. 2017;17(8):1013-1017.
34. Ruella M, Maus MV. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput Struct Biotechnol J. 2016;14:357-362.
35. Jacoby E, Nguyen SM, Fountaine TJ, et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Commun. 2016;7:12320.
36. Paul MR, Wong V, Aristizabal P, Kuo DJ. Treatment of recurrent refractory pediatric pre-B acute lymphoblastic leukemia using inotuzumab ozogamicin monotherapy resulting in CD22 antigen expression loss as a mechanism of therapy resistance. J Pediatr Hematol Oncol. 2019;41(8):e546-e549.
37. Reinert J, Beitzen-Heineke A, Wethmar K, Stelljes M, Fiedler W, Schwartz S. Loss of CD22 expression and expansion of a CD22 dim subpopulation in adults with relapsed/refractory B- lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin. Ann Hematol. 2021;100(11):2727-2732.
38. Kantarjian HM, Stock W, Cassaday RD, et al. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia in the INO-VATE trial: CD22 pharmacodynamics, efficacy, and safety by baseline CD22. Clin Cancer Res. 2021;27(10):2742-2754.
39. Fingrut W, Davis W, Dallas K, et al. Inotuzumab ozogamicin as salvage therapy for relapsed B-cell acute lymphoblastic leukemia with only very dim expression of Cd22 on circulating blasts. A case report. Clin Lymphoma Myeloma Leuk. 2019;19:S184.
40. Kantarjian HM, DeAngelo DJ, Advani AS, et al. Hepatic adverse event profile of Inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017;4(8):e387-e398.
41. Marks DI, Kebriaei P, Stelljes M, et al. Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2019;25(9):1720-1729.
42. Kebriaei P, Cutler C, de Lima M, et al. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018;53(4):449-456.
43. Wan X, Yang X, Yang F, et al. Outcomes of anti-CD19 CAR-T treatment of pediatric B-ALL with bone marrow and extramedullary relapse. Cancer Res Treat. 2022;54(3):917-925.
Haematologica | 107 September 2022
2071